JY-232 in Multiple Myeloma: NCT07336823 Clinical Landscape Report 2026
Explore the PatSnap Life Sciences MCP marketplace
This Clinical Landscape Report was built with PatSnap Life Sciences MCP workflows. Clinical Trials MCP supplies protocol and result records, Drug & Asset MCP adds asset context, and Company & Deal Intelligence MCP resolves sponsor background. Use the same structured MCP building blocks in your research workflow.
Data snapshot: 28 September 2026. This strategic research report is not medical, regulatory or investment advice. Trial status and dates can change.
Early Phase 1
Clinical phase
Recruiting
Recruitment status
9
Planned enrollment
2028-12-31
Primary-completion proxy
Executive view
NCT07336823 evaluates JY-232 in Multiple Myeloma. The disclosed sponsor is Shenzhen Genocury Biotech Co., Ltd., the design is Interventional, and the geographic footprint is China. The first listed primary endpoint is Incidence of Treatment Related adverse events (AEs), assessed over Up to 2 years after infusion.
The key landscape question is whether this protocol can generate a clinically interpretable signal relative to nearby programs. Phase alone is not a measure of evidence quality. Endpoint relevance, comparator choice, masking, enrollment feasibility, patient selection, country coverage and follow-up must be considered together.
PatSnap MCP Servers make this assessment reproducible by keeping protocol facts, result evidence, asset attributes and sponsor identity in separate structured calls.
How the MCP evidence stack was assembled
Clinical Trials MCP clinical_trial_fetch retrieved the design, outcomes, phase, status, enrollment, sponsor, countries and timing for NCT07336823 and selected peers. clinical_trial_result_fetch supplied detailed result records from the wider Multiple Myeloma landscape. Drug & Asset MCP drug_fetch was queried for JY-232, while Company & Deal Intelligence MCP organization_fetch was queried for Shenzhen Genocury Biotech Co., Ltd..
This separation reduces a common diligence error: treating a registry label, a company description or a result excerpt as if each represented the complete evidence package. Explore the source workflow at the PatSnap MCP marketplace.
Trial landscape table
| Trial | Asset / intervention | Phase / status | Sponsor | Geography | Primary endpoint | Readout proxy |
|---|---|---|---|---|---|---|
| NCT07336823 | JY-232 | Early Phase 1 / Recruiting | Shenzhen Genocury Biotech Co., Ltd. | China | Incidence of Treatment Related adverse events (AEs) Up to 2 years after infusion | 2028-12-31 |
| NCT07421856 | SENL-103 | Phase 1/2 / Not yet recruiting | Hebei Senlangbio Biotechnology Co., Ltd. | Geography not reported | Maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) after S103 infusion 28 days | 2028-02-01 |
| NCT07413809 | Tropisetron hydrochloride | Phase 3 / Recruiting | Sponsor not reported | China | Complete Response (CR) 24 to 240 hours after chemotherapy | 2027-09-01 |
| NCT07409246 | ABBV-438 | Phase 1 / Recruiting | AbbVie, Inc. | United States, Japan, China, Israel | Number of Participants With Adverse Events (AE) Up to Approximately 69.5 Months | 2031-11-01 |
| NCT07409454 | Gamgertamig | Phase 2 / Recruiting | Hematology Hospital of Chinese Academy of Medical Sciences | China | Minimal residual disease (MRD) negativity conversion rate Up to 24 months | 2027-12-31 |
The table aligns endpoints, sponsors, phases, geographies and readout proxies. It is descriptive, not a head-to-head efficacy comparison. Differences in population, baseline risk, intervention schedule and follow-up can dominate apparent cross-trial differences.
Reproduce the trial-to-asset workflow with PatSnap MCP
Protocol design and endpoint interpretation
NCT07336823 is a Early Phase 1, recruiting study with 9 planned participants. Allocation is N/A, masking is None (Open Label), and the intervention model is Single Group Assignment.
The primary endpoint is “Incidence of Treatment Related adverse events (AEs)” over “Up to 2 years after infusion.” The retrieved endpoint description is: The frequency, severity, and laboratory findings of all adverse events/serious adverse events are included..
Interpretation should test whether the endpoint captures a clinically meaningful change, whether its time horizon matches the proposed biology, and whether treatment discontinuation or missing data can bias the estimate. The planned enrollment of 9 should be assessed against expected effect size, event frequency, multiplicity, subgroup plans and attrition.
No named control drug was returned in the protocol field set. A placebo comparator can strengthen internal efficacy assessment, while an active comparator may better test clinical differentiation. Single-arm and open-label programs require greater weight on objective outcomes, independent assessment and external benchmarks.
Indexed readouts in the surrounding landscape
5 recent result records were selected as contextual evidence for Multiple Myeloma. These records do not establish direct evidence for NCT07336823 unless the registration number matches.
Autologous Stem Cell Transplant With Pomalidomide (CC-4047®) Maintenance Versus Continuous Clarithromycin/ Pomalidomide / Dexamethasone Salvage Therapy in Relapsed or Refractory M…
Phase 2; n=23; No numerical result field reported Source: https://clinicaltrials.gov/ct2/show/results/NCT01745588
Open Label, Phase 2, Single-Arm Study of Selinexor, Daratumumab, Carfilzomib and Dexamethasone for High-Risk, Relapsed and Relapsed/Refractory Multiple Myeloma Patients Who Have R…
Phase 2; n=8; ORR = 75.0 percentage of participants (95% Confidence Interval, 34.9 - 96.8) Source: https://clinicaltrials.gov/ct2/show/results/NCT04756401
AbbVie Announces Positive Topline Results from the Phase 3 CERVINO Trial Showing Etentamig Significantly Improved Response Rate and Progression-Free Survival in Patients with Rela…
Phase 3; n=393; ORR(First planned efficacy interim analysis; median follow-up 11.4 months.) = 45.7 % (95%CI, 38.59 - 52.91) Met; ORR(First planned efficacy interim analysis; median follow-up 11.4 months.) = 74.0 % (95%CI, 67.25 - 79.97) Met Source: https://www.prnewswire.com/news-releases/abbvie-announces-positive-topline-results-from-the-phase-3-cervino-trial-showing-etentamig-significantly-improved-response-rate-and-progression-free-survival-in-patients-with-relapsedrefractory-multiple-myeloma-302868290.html
Result fields should be reconciled with the source record before quantitative comparison. Population definitions, analysis sets, dose cohorts, estimands, confidence intervals, rescue therapy and follow-up can materially change the meaning of a numerical endpoint. Clinical Trials MCP supports repeatable refreshes as result records change.
Asset and sponsor context
JY-232 is indexed as in vivo CAR-T therapy with target not reported biology and a global stage of Early Phase 1. The asset profile lists Shenzhen Genocury Biotech Co., Ltd. as an originator or developer.
Shenzhen Genocury Biotech Co., Ltd. is indexed in China. The organization record is used to resolve sponsor identity. The record lists 3 development-stage drug assets.
For execution diligence, monitor sponsor ownership, collaborator additions, site expansion, protocol amendments and enrollment revisions. A change in ownership or geography can alter operational confidence as well as the commercial meaning of a future readout.
Development white space
- Endpoint white space. Determine whether a more patient-relevant outcome, longer durability window or blinded central assessment would resolve uncertainty left by the current endpoint.
- Population white space. Test biomarker-defined, treatment-line or risk-stratified subgroups where effect size and unmet need could be clearer.
- Comparator white space. Identify whether the study can support differentiation against the current standard of care rather than only activity against baseline or placebo.
- Geographic white space. Assess whether the disclosed footprint supports recruitment, regulatory transferability and commercial generalizability.
- Sequencing white space. Clarify whether JY-232 is intended for monotherapy, combination, maintenance, rescue or an earlier treatment line.
White space should be framed as an unanswered development question, not merely an unoccupied mechanism label. A credible program closes a measurable clinical uncertainty with a design that can be executed and interpreted.
Strategic implications and next readouts
For sponsors, the endpoint hierarchy, safety window, enrollment pace and protocol amendment history should all support the same target product profile. Advancement criteria should be set before the readout and tied to clinical effect, uncertainty, tolerability and operational feasibility.
For business-development teams, differentiation may come from a sharper population, stronger comparator, more durable benefit, simpler delivery or clearer sequencing role. For investors, the central risk is evidence quality relative to time and capital, not the phase label in isolation.
Track recruitment status, enrollment changes, primary-completion timing, endpoint revisions, new result records, sponsor ownership and collaborator changes. Re-run the PatSnap MCP workflow when a surrogate becomes a clinical outcome, a single-country study expands, the comparator changes or a new result materially shifts the competitive benchmark.
Source trail and bottom line
Anchor trial: NCT07336823
Protocol source: https://clinicaltrials.gov/study/NCT07336823
MCP sources: Clinical Trials MCP (clinical_trial_fetch and clinical_trial_result_fetch); Drug & Asset MCP (drug_fetch); Company & Deal Intelligence MCP (organization_fetch).
Data snapshot: 28 September 2026.
JY-232 in Multiple Myeloma is best understood through the interaction of protocol design, surrounding readouts, asset context and sponsor execution. The current record makes Incidence of Treatment Related adverse events (AEs) and 2028-12-31 the leading decision points.
Build and refresh clinical landscape reports with PatSnap MCP
